272 related articles for article (PubMed ID: 23430957)
21. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
23. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Vanaja GR; Ramulu HG; Kalle AM
Cell Commun Signal; 2018 May; 16(1):20. PubMed ID: 29716651
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
26. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
[TBL] [Abstract][Full Text] [Related]
27. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
Formisano L; Guida N; Laudati G; Mascolo L; Di Renzo G; Canzoniero LM
J Pharmacol Exp Ther; 2015 Feb; 352(2):236-43. PubMed ID: 25467131
[TBL] [Abstract][Full Text] [Related]
28. Multiple roles of SOCS proteins: differential expression of SOCS1 and SOCS3 in atherosclerosis.
Liang X; He M; Chen T; Liu Y; Tian YL; Wu YL; Zhao Y; Shen Y; Yuan ZY
Int J Mol Med; 2013 May; 31(5):1066-74. PubMed ID: 23545584
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation.
Glenisson W; Castronovo V; Waltregny D
Biochim Biophys Acta; 2007 Oct; 1773(10):1572-82. PubMed ID: 17610967
[TBL] [Abstract][Full Text] [Related]
30. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Sekhavat A; Sun JM; Davie JR
Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
32. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
Lehmann M; Hoffmann MJ; Koch A; Ulrich SM; Schulz WA; Niegisch G
J Exp Clin Cancer Res; 2014 Jul; 33(1):59. PubMed ID: 25011684
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase 8 regulates cortactin deacetylation and contraction in smooth muscle tissues.
Li J; Chen S; Cleary RA; Wang R; Gannon OJ; Seto E; Tang DD
Am J Physiol Cell Physiol; 2014 Aug; 307(3):C288-95. PubMed ID: 24920679
[TBL] [Abstract][Full Text] [Related]
35. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes.
Madonna S; Scarponi C; Sestito R; Pallotta S; Cavani A; Albanesi C
J Immunol; 2010 Aug; 185(4):2467-81. PubMed ID: 20644166
[TBL] [Abstract][Full Text] [Related]
36. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.
Baus D; Pfitzner E
Int J Cancer; 2006 Mar; 118(6):1404-13. PubMed ID: 16206268
[TBL] [Abstract][Full Text] [Related]
37. [Study of hypermethylation of SOCS gene in typical myeloproliferative disease].
Qin W; Li LL; Lu HN; Huang BB; Xiu B; Bo LJ; Gao QM; Zhang WJ; Fu JF
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):772-6. PubMed ID: 22339915
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
39. Effects of trichostatin A on neuronal mu-opioid receptor gene expression.
Lin YC; Flock KE; Cook RJ; Hunkele AJ; Loh HH; Ko JL
Brain Res; 2008 Dec; 1246():1-10. PubMed ID: 18950606
[TBL] [Abstract][Full Text] [Related]
40. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
Liu HL; Chen Y; Cui GH; Zhou JF
Acta Pharmacol Sin; 2005 May; 26(5):603-9. PubMed ID: 15842781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
